Forte Biosciences (FRA:37T) Total Debt per Share: €0.00 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:37T Forte Biosciences Inc FRA:37T
33 GF Score
Price €65.00
! 3 Warning Signs
View Full Analysis

What is Forte Biosciences Total Debt per Share?

Forte Biosciences FRA:37T 33 Total Debt per Share is €0.00 as of Jun. 2026. GuruFocus rates FRA:37T with a GF Score™ of 33/100. The stock has 3 warning signs investors should review.

€0.00 (As of Jun. 2026)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Forte Biosciences's Total Debt Per Share for the quarter that ended in Jun. 2026 was €0.00.


Forte Biosciences Total Debt per Share Historical Data

* Premium members only.

The historical data trend for Forte Biosciences's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Forte Biosciences Total Debt per Share Chart

Forte Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Debt per Share
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Forte Biosciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Debt per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:37T
33GF Score
Forte Biosciences Inc FRA:37T
Total Debt per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Forte Biosciences Total Debt per Share Calculation

Forte Biosciences's Total Debt Per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Forte Biosciences's Total Debt Per Share for the quarter that ended in Jun. 2026 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Debt per Share →
What does a Total Debt per Share of €0.00 mean?
Forte Biosciences (FRA:37T) has a Total Debt per Share of €0.00 as of Jun. 2026. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Forte Biosciences and its competitors.
Is Forte Biosciences' Total Debt per Share too high?
Forte Biosciences' current Total Debt per Share is €0.00. Overall, Forte Biosciences has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Forte Biosciences' Total Debt per Share compare to WVE and SVRA?
Forte Biosciences' Total Debt per Share of €0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Debt per Share for a Biotechnology company?
A good Total Debt per Share depends on the Biotechnology industry context. However, Total Debt per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Debt per Share mean?
A high Total Debt per Share can signal that a stock is expensive relative to its fundamentals. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Forte Biosciences and its competitors. Forte Biosciences's current Total Debt per Share is €0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Forte Biosciences stock overvalued right now?
Forte Biosciences (FRA:37T) has a current Total Debt per Share of €0.00. The current Total Debt per Share is €0.00. Forte Biosciences' overall GF Score™ is 33/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Debt per Share calculated?
Total Debt per Share is calculated from a company's financial statements. For Forte Biosciences (FRA:37T), the current Total Debt per Share is €0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Forte Biosciences Business Description

Other Exchanges FBRX:USA
Address 3060 Pegasus Park Drive, Building 6, Dallas, TX, USA, 75247
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.
33GF Score

Get the complete analysis for FRA:37T

Total Debt per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€65.00
Price